We are live on ! Find out more
JNCE

Jounce Therapeutics, Inc. Common Stock
JNCE

Delisted

JNCE was delisted on the 3rd of May, 2023.

Back to rankings

104 hedge funds and large institutions have $194M invested in Jounce Therapeutics, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 25 increasing their positions, 41 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 15

2% more funds holding

Funds holding: 102 → 104 (+2)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

6% less capital invested

Capital invested by funds: $207M → $194M (-$13.3M)

26% less call options, than puts

Call options by funds: $1.06M | Put options by funds: $1.44M

39% less repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 41

Holders
104
Holders Change
+2
Holders Change %
+1.96%
% of All Funds
1.84%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
17
Increased
25
Reduced
41
Closed
15
Calls
$1.06M
Puts
$1.44M
Net Calls
-$380K
Net Calls Change
-$559K

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$13.2M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$10.7M
3
SI
Sofinnova Investments
California
+$7.2M
4
BlackRock
BlackRock
New York
+$2.62M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$817K

Top Sellers

Rank Fund Capital Flow
1
TGI
TRV GP II
Massachusetts
-$8.02M
2
CS
Candriam SCA
Luxembourg
-$2.88M
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$2.35M
4
Renaissance Technologies
Renaissance Technologies
New York
-$1.32M
5
Russell Investments Group
Russell Investments Group
United Kingdom
-$901K
Name Holding Trade Value Shares
Change 		Change in
Stake
JP Morgan Chase
26
JP Morgan Chase
New York
$853K -$31.3K -4,018 -3%
Fidelity Investments
27
Fidelity Investments
Massachusetts
$824K -$351K -45,100 -28%
Wells Fargo
28
Wells Fargo
California
$788K +$158K +20,238 +22%
T. Rowe Price Associates
29
T. Rowe Price Associates
Maryland
$735K +$817K +104,996 New
Jacobs Levy Equity Management
30
Jacobs Levy Equity Management
New Jersey
$705K -$639K -82,094 -45%
Connor, Clark & Lunn Investment Management (CC&L)
31
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$665K -$42.5K -5,457 -5%
CAM
32
Congress Asset Management
Massachusetts
$646K -$9.96K -1,280 -1%
Squarepoint
33
Squarepoint
New York
$602K +$420K +53,997 +169%
Russell Investments Group
34
Russell Investments Group
United Kingdom
$504K -$901K -115,792 -62%
Bank of New York Mellon
35
Bank of New York Mellon
New York
$504K -$889K -114,247 -61%
State of Wisconsin Investment Board
36
State of Wisconsin Investment Board
Wisconsin
$489K +$230K +29,500 +73%
AllianceBernstein
37
AllianceBernstein
Tennessee
$391K – – –
Axa
38
Axa
France
$374K – – –
HSA
39
Hussman Strategic Advisors
Maryland
$357K -$397K -51,000 -50%
ZCM
40
Ziegler Capital Management
Illinois
$352K -$45.5K -5,842 -10%
YMRC
41
Yorktown Management & Research Company
Virginia
$344K -$15.6K -2,000 -4%
New York State Common Retirement Fund
42
New York State Common Retirement Fund
New York
$343K -$5.45K -700 -1%
Millennium Management
43
Millennium Management
New York
$335K +$194K +24,966 +109%
First Trust Advisors
44
First Trust Advisors
Illinois
$290K -$12.6K -1,616 -4%
LPL Financial
45
LPL Financial
California
$289K -$9.92K -1,275 -3%
SEI Investments
46
SEI Investments
Pennsylvania
$273K -$764K -98,223 -72%
First Manhattan
47
First Manhattan
New York
$268K -$43.6K -5,600 -13%
Goldman Sachs
48
Goldman Sachs
New York
$249K -$19.8K -2,540 -7%
DCM
49
Dupont Capital Management
Delaware
$244K -$20.3K -2,605 -7%
Morgan Stanley
50
Morgan Stanley
New York
$243K +$5.68K +730 +2%
1
2
3 4 5

JNCE Hedge Fund Activity: Q4 2020 in Review

104 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Jounce Therapeutics, Inc. Common Stock (JNCE) for Q4 2020, worth a combined $194M — down 6.4% from $207M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new JNCE positions and 15 closed out — a net gain of 2 holders — while 25 added to existing stakes and 41 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $13.2M. The largest seller was TRV GP II, cutting an estimated $8.02M.

  • 104 institutional investors held Jounce Therapeutics, Inc. Common Stock (JNCE) as of Q4 2020, up from 102 in Q3 2020.
  • Funds reported $194M of Jounce Therapeutics, Inc. Common Stock stock for Q4 2020, down 6.4% quarter-over-quarter.
  • 17 funds opened new Jounce Therapeutics, Inc. Common Stock positions in Q4 2020 and 15 closed out, a net change of +2 holders.
  • The largest Jounce Therapeutics, Inc. Common Stock buyer in Q4 2020 was Citadel Advisors, an estimated $13.2M added.
  • The largest Jounce Therapeutics, Inc. Common Stock seller in Q4 2020 was TRV GP II, an estimated $8.02M sold.

Based on aggregated 13F filings for Q4 2020.